Perspectives for Cancer Care and Research in Central and Eastern Europe
- PMID: 36463856
- PMCID: PMC10015746
- DOI: 10.1159/000528487
Perspectives for Cancer Care and Research in Central and Eastern Europe
Abstract
Background: Discrepancies between the outcomes of cancer patients between Western European and Central and Eastern European (CEE) countries have often been observed. Despite the enormous economic and civilizational progress made in these countries after the abolishment of the communist regime, structural problems persist.
Summary: The present article reviews the domains of medical oncology education, human resources in oncology, cancer care, and clinical research in CEE in order to comprehensively assess the current situation and needs, describe important initiatives, and also propose ways to improving cancer outcomes in the region. Activities are under way to address these issues in national action plans to divert funding into oncology-related education, research, the purchase of equipment, and the attainment of modern hospital organization and structures.
Key message: Over the past more than 30 years, CEE countries have made enormous economic and societal progress. Nevertheless, challenges especially in the health care sector persist.
Keywords: Cancer care; Central and Eastern Europe; Clinical research; Education; Human resources; Oncology.
© 2022 The Author(s). Published by S. Karger AG, Basel.
Conflict of interest statement
T.C.: receipt of honoraria or consultation fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, MSD, Pfizer, and Takeda; B.S.: honorary and consultancy fee from Astellas, Jansen, and AstraZeneca; M.D.: advisory role and speaker fees from Aventis, Astellas, AstraZeneca, Amgen, Ipsen, Janssen, Novartis, Pfizer, Roche, Sandoz, BMS, MSD, Eli Lilly, Servier, and Takeda; J.J.: advisory roles in AstraZeneca, MSD, and Exact Sciences. C.T and C.C.Z.: institution (CECOG): BMS, MSD, Pfizer, AstraZeneca, Merck KgA, Amgen, Servier, Eli Lilly, Takeda, Daiichi Sankyo, Roche, Boehringer Ingelheim, Celgene, and Halozyme. C.C.Z.: consultancies and speaker's honoraria from Athenex, MSD, Imugene, AstraZeneca, Servier, and Eli Lilly; patents for Imugene.
Figures
References
-
- European union of medical specialists Medical Specialities. 2013.
-
- Benstead K, Lara PC, Andreopoulos D, Bibault JE, Dix A, Eller YG, et al. Recommended ESTRO core curriculum for radiation oncology/radiotherapy 4th edition. Radiother Oncol. 2019 Dec;141:1–4. - PubMed
-
- Benstead K, Turhal NS, O'Higgins N, Wyld L, Czarnecka-Operacz M, Gollnick H, et al. Multidisciplinary training of cancer specialists in Europe. Eur J Cancer. 2017 Sep;83:1–8. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
